Please login to the form below
Kanuma
This page shows the latest Kanuma news and features for those working in and with pharma, biotech and healthcare.
Amgen takes aim at Alexion’s patents for Soliris
Alexion’s other products such as lysosomal acid lipase deficiency treatment Kanuma (sebelipase alfa) and Strensiq (asfotase alfa) for hypophosphatasia have a long way to go before they bring in enough
Latest news
-
Alexion adds to pipeline with $1.2bn Syntimmune buy
With patents due to expire in the US and Europe in the next three years – and new drugs such as lysosomal acid lipase deficiency treatment Kanuma and Strensiq for hypophosphatasia still
-
Alexion uses priority review voucher for Soliris follow-up
Alexion is sitting on a pair of PRVs awarded for earlier approvals for rare disease therapies (Strensiq and Kanuma), and it’s a measure of the importance the company attaches to ... impact. And that’s particularly important, as newer products such as
-
Alexion adds to pipeline rebuild with $855m Wilson buy
However, its 2015 takeover of Synageva for $8.4bn has been less successful, with Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency (LAL-D) so far failing to deliver its expected
-
NICE broadens access to Alexion's rare disease drug Strensiq
NICE also turned down Alexion's other new enzyme replacement product - £500, 000 per year Kanuma (sebelipase alfa) for lysosomal acid lipase deficiency (LAL-D) - earlier this year.
-
NICE blocks second Alexion rare disease drug in a week
Patients with the rare inherited genetic disorder lysosomal acid lipase deficiency (LAL-D) will not be able to get routine treatment with Alexion's Kanuma, says NICE. ... The Kanuma decision has been met with consternation by the Society for
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Assessing the impact of rarity on French HTA and pricing decisions
The ATCs for the reimbursed products with the highest ASMRs (Kalydeco, Strensiq: ASMR 2; Kanuma: ASMR 3) were among the highest ATCs in the analysis, suggesting a relationship between ASMR and
-
Pharma deals in May 2015
This agreement brings access to Kanuma (sebelipase alfa) which is in registration for the treatment of lysosomal acid lipase (LAL) deficiency. ... Corporate acquisition. Rare diseases portfolio including Kanuma (sebelipase alpha) for LAL deficiency.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
